<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>PROSPECTUS SUPPLEMENT (To Prospectus dated May 7, 2025) American Depositary Shares Representing 17,500,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,250,000 American Depositary Shares Representing 1,250,000 Ordinary Shares American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>PROSPECTUS SUPPLEMENT (To Prospectus dated May 7, 2025) American Depositary Shares Representing 17,500,000 Ordinary Shares Pre-Funded Warrants to Purchase up to 1,250,000 American Depositary Shares Representing 1,250,000 Ordinary Shares American Depositary Shares Issuable Upon Exercise of the Pre-Funded Warrants</h1>

    <table>
      <tr><th>Ticker</th><td>CMPS</td></tr>
      <tr><th>Float</th><td>N/A</td></tr>
      <tr><th>IO</th><td>N/A</td></tr>
      <tr><th>MC</th><td>N/A</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>SEC filing (Form 424B5) — Prospectus supplement by COMPASS Pathways plc for an underwritten offering of 17,500,000 American Depositary Shares (ADSs) and pre-funded warrants to purchase up to 1,250,000 ADSs. Offering price is $8.00 per ADS and $7.9999 per pre-funded warrant; exercise price of each pre-funded warrant is $0.0001. Net proceeds (excluding any exercise proceeds) expected to be approximately $140.5 million; intended uses include funding Phase 3 COMP005/COMP006 trials, a Phase 2b/3 PTSD trial, commercial readiness and general corporate purposes. Underwriters have a 30-day option to purchase up to 2,812,500 additional ADSs; underwriting discount is $0.48 per ADS. Post-offering ADS counts provided (e.g., 113,502,044 ADSs outstanding assuming no exercise; 114,752,044 if pre-funded warrants are immediately exercised). Recent clinical update included: COMP006 announced Feb 17, 2026 primary endpoint met (25 mg vs 1 mg, mean difference -3.8, p < 0.001); COMP005 previously met primary endpoint. Key terms: pre-funded warrants not expected to trade on an exchange, 19.99% beneficial ownership limitation, 60-day lock-up for insiders, expected delivery ~Feb 20, 2026. Filing includes risk factors (dilution, volatility, going concern if offering not completed) and preliminary cash estimate of ~$149.6 million as of Dec 31, 2025.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Issuer: COMPASS Pathways plc filed a registered prospectus supplement on Form 424B5 for the offering.</li><li>Offering size: 17,500,000 ADSs and pre-funded warrants to purchase up to 1,250,000 ADSs at $8.00 / $7.9999 each respectively.</li><li>Net proceeds expected ~ $140.5 million (excluding pre-funded warrant exercise proceeds) to fund Phase 3 TRD trials, PTSD trial, commercial readiness and general purposes.</li><li>Underwriters granted option to purchase up to 2,812,500 additional ADSs (30 days).</li><li>Recent clinical milestone: COMP006 Phase 3 primary endpoint met (25 mg vs 1 mg, mean difference -3.8, p < 0.001); COMP005 previously met its primary endpoint.</li><li>ADSs are listed on Nasdaq Global Select Market under ticker CMPS.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Immediate dilution to new investors: reported immediate dilution of $6.43 per ADS (as adjusted net tangible book value $1.57 per ADS vs $8.00 offering price).</li><li>Pre-funded warrants have no established public trading market and are not intended to be listed, limiting liquidity.</li><li>Company states there is substantial doubt about its ability to continue as a going concern if this offering is not completed (estimated cash ~$149.6M as of 12/31/2025).</li><li>Pre-funded warrants include a beneficial ownership limitation (default cap 19.99%) and provisions (automatic cashless exercise on certain fundamental transactions) that could affect holders.</li><li>Offering will increase shares eligible for resale and may cause further dilution (multiple outstanding warrants/options noted: e.g., 35,059,448 ADS Warrants, 12,324,700 PIPE Warrants, 8,700,000 outstanding pre-funded warrants as of 9/30/2025).</li></ul>
    </div>

    <div class="section">
      <a href="https://www.sec.gov/Archives/edgar/data/1816590/000162828026009499/0001628280-26-009499-index.htm" target="_blank">Original Article</a>
    </div>

    <div class="small">CMPS • TradersLink AI News</div>
  </div>
</body>
</html>